AstraZeneca is working in collaboration with the molecular diagnostics firm Myriad Genetics’ for its tes...Read more
Singapore - US biotech giant Moderna Therapeutics – which is backed by Singapore-based EDBI and Seq...Read more
Europe’s largest privately held biotech company, Germany-based BioNTech, has raised $270 million to supp...Read more
South Korea – leading biosimilars opportunities for Asia
Historically, Asia has led in generics adoption and now, with more than 300 biosimilars under development, Asia is one of the leading regions for global biosimilars development. The foundations have been laid for the biosimilar industry in Korea, providing an opportunity for the region to become a global center for manufacturing and adoption of biosimilars in the next few decades. Just as Indian companies have carved out a leading position in the generic drug market, South Korean companies are poised to take leading positions in the biosimilars industry in the coming years.